Showing results (11-20 of 395) with videos related to
Sort By:
Pageof 40
The Psychiatric Quarterly|October 30, 1998
Treatment refractory schizophrenia: how should we proceed?Z A SharifCurrent Drug Targets|April 30, 2010
Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of actionNajam A SharifAnnals of the New York Academy of Sciences|January 1, 1989
Quantitative autoradiography of TRH receptors in discrete brain regions of different mammalian speciesN A SharifNeural Regeneration Research|July 8, 2022
Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitorsNajam A SharifBrain Research|May 24, 1988
Chronic prolactin, gonadal and thyroid hormone treatments in vivo alter levels of TRH and muscarinic receptors in male and female rat tissuesN A SharifCurrent Opinion in Pharmacology|January 3, 2024
Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drugNajam A SharifJournal of Neurochemistry|February 1, 1988
Chemical and surgical lesions of rat olfactory bulb: changes in thyrotropin-releasing hormone and other systemsN A SharifThe Journal of Clinical Psychiatry|December 10, 1998
Common treatment goals of antipsychotics: acute treatmentZ A SharifJournal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|January 20, 2015
Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axesNajam A SharifJournal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|January 12, 2018
iDrugs and iDevices Discovery Research: Preclinical Assays, Techniques, and Animal Model Studies for Ocular Hypotensives and NeuroprotectantsNajam A SharifPageof 40